Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort.
Ko Eun KimPil Sung YangEunsun JangSung Jin KimBoyoung JoungPublished in: Yonsei medical journal (2019)
Dual antiplatelet or triple therapy increased the risk of VH significantly, compared to warfarin monotherapy. Considering the low efficacy of preventing ischemic stroke and high risk of bleeding, dual or triple therapy using warfarin and antiplatelet agents should be avoided to prevent VH in AF patients.
Keyphrases
- atrial fibrillation
- health insurance
- oral anticoagulants
- direct oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- end stage renal disease
- heart failure
- healthcare
- quality improvement
- ejection fraction
- percutaneous coronary intervention
- newly diagnosed
- chronic kidney disease
- mental health
- prognostic factors
- venous thromboembolism
- peritoneal dialysis
- stem cells
- acute coronary syndrome
- mitral valve
- double blind
- drug induced